Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

GLP-1 drugs like Ozempic show widespread promise beyond weight loss/diabetes, but cost and supply limit broader adoption.

GLORY-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD). DREAMS-1: A Phase 3 trial ...

Galmed Pharmaceuticals Ltd. ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three ...

A game-changing medication known for diabetes and weight loss might also hold the key to improving liver health for millions of Americans.

While GLP-1 receptor agonists (e.g., semaglutide, tirzepatide ... CG-0416 is a novel liver-targeted THR-β prodrug in development for MASH & obesity-related complications. Its tissue-selective ...

While GLP-1 receptor agonists (e.g., semaglutide, tirzepatide ... CG-0416 is a novel liver-targeted THR-β prodrug in development for MASH & obesity-related complications.